Compare Immunovant Inc. Common Stock (IMVT) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.47 (market cap $27.76B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 4.2× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| IMVT | LQD | |
|---|---|---|
Market Cap | $6.62B | $27.76B |
Volume | 1,131,364 | 30,088,564 |
Sector | Health | Fixed Income |
52-Week High | $44.96 | $112.91 |
52-Week Low | $17.03 | $101.83 |
Typical Hold Time | 0 Days | 125 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LQD trades at $102.12, down 0.02% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The ETF faces headwinds from rising bond yields and a significant 53.1% increase in short interest reported as of September 15, 2026. Recent dividends include $0.44 and $0.46 payouts scheduled through October 2026, providing income support.
Outlook remains cautious due to persistent bond market volatility and higher interest rates, which pressure corporate bond ETFs. Investment opportunities lie in the 4.8% yield and high-quality portfolio, but risks include further yield spikes and economic slowdowns affecting credit quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
